Phoenix Life
Sciences International Announces Michael Gobel as Finance
Advisor
DENVER, CO February X, 2019
-- InvestorsHub NewsWire -- Phoenix
Life Sciences International Limited (OTC: PLSI) ("Phoenix Life"), an
international adaptive healthcare solutions company, today
announced that Michael Gobel has joined as the company's Board of
Directors to help the company navigate the next steps for larger
capital investment and compliance for a planned uplisting to
NASDAQ.
"Financial management and a
strong capitalized organization both play large roles in the
progression of our international expansion," said Phoenix Life
Sciences International CEO Martin Tindall. "Michael Gobel's
extensive experience in risk assessment, financial guidance and
balancing various capital opportunities will be imperative in
implementing a successful long-term financial
strategy."
Gobel holds a Master's
degree in Applied Finance from Macquarie University in
Sydney and has more than three decades of experience
in the finance industry. He serves as Company Director and
Portfolio Manager, managing investments and associated risk in
local and overseas equity markets. Additionally, Gobel
currently serves as a consultant on economic developments and
major projects while also representing a variety of interests
to federal ministers and senior government advisors. Michael
is on a number of Boards including as Deputy Chairman of an
Australian Bank, assisting in guiding the company's corporate
governance and strategy, ensuring best practices and encouraging a
culture of proactive risk management.
"Assessing and choosing
financial decisions and managing reducing risk factors will help
ensure that Phoenix Life achieves forward progression in company
milestones and continual success," said Phoenix Life's new Board
Member, Michael Gobel. "I look forward to working with a company
that has many innovative and potentially revolutionary
goals."
To learn more about Phoenix
Life Sciences International, please visit
http://www.phoenixlife.co
About Phoenix
Life Sciences International Limited
Phoenix Life Sciences
International Limited is an adaptive healthcare solutions company.
Our business is to advance research and integrate programs and
manufacturing of products that target and treat diabetes, pain,
cancer, and address psychological, gastrointestinal, autoimmune,
neurological and sleep disorders. We strive to create partnerships
and integrate these programs for human health into communities
worldwide as part of our Global Health
Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the "Companies") may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
"plan", "forecast", "anticipates", "estimate", "project", "intend",
"expect", "should", "believe," and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to, known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in the Company's filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to the Companies herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. The Companies disclaim any obligation to update
forward-looking statements contained in this press release, except
as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements have not
been evaluated by the FDA and therefore the products sold by
Phoenix Life Sciences International are not available in the
U.S.
LEGAL
DISCLOSURE
Phoenix Life Sciences
International does not sell or distribute any products in the
United States that are in violation of the United States Controlled
Substances Act (US.CSA). This company does not grow, sell, and
distribute cannabis-based products in the United States and is
solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States.
Investor
Contact:
Phone: 1.888.717.5655 or
international +1.720.699.7222
E-mail:
investor.relations@phoenixlife.co
Media
Contact:
Kathryn
Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089